Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of lifileucel plus pembrolizumab versus pembrolizumab alone in previously untreated advanced melanoma
MOH_2024-02-05_013238Phase 3Not yet recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Lifileucel plus pembrolizumab with Pembrolizumab with optional crossover period (2 arms). Primary endpoint: Tumor reduction / tumor disappearance. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
lifileucelpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2024-02-05_013238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-05_013238.